TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock

Stock Information for TriSalus Life Sciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About TriSalus Life Sciences Inc.

TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025
TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery(TM)
TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance
TriSalus Life Sciences to Participate in Upcoming Investor Conferences
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025
TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call
TriSalus Life Sciences to Participate in Upcoming September Investor Conferences
TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.